Company Overview of Mitomics Inc.
Mitomics Inc. engages in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions in Canada and internationally. It develops mitochondria DNA based biomarkers for the screening, diagnosis, and management of cancer and gynecology disease states, including prostate, breast, lung, colorectal, ovarian, endometrial, cervical, bladder, testicular, and skin cancers, as well as endometriosis. The company offers Prostate Core Mitomic Test to identify men at high risk of having a prostate tumor missed by the prostate biopsy procedure, without the need for further invasive biopsy procedures. Mitomics Inc. was formerly known as Genesis Gen...
290 Munro Street
Thunder Bay, ON P7A 7T1
Founded in 2001
Key Executives for Mitomics Inc.
Chief of Research & Laboratory Operations
Compensation as of Fiscal Year 2014.
Mitomics Inc. Key Developments
Mitomics Inc. Announces U.S. Sales and Marketing Agreement with Sterling Pathology National Laboratories
Jan 7 13
Mitomics Inc. announced it has entered into a sales and marketing agreement for the Prostate Core Mitomic Test(TM) (PCMT(TM)) with Sterling Pathology National Laboratories. Under the agreement, Sterling Pathology National Laboratories will make PCMT available through their team of sales representatives to urologists throughout the United States, on a non-exclusive basis. PCMT is one of the most accurate and safest tests currently on the market for the detection of prostate cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries